Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cuc D treatment also showed inhibition of tumor growth in PrCa xenograft mouse model with concomitant decrease in the expression of GLUT1, PCNA and restoration of miR-132.
|
30875788 |
2019 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results suggest that targeting PCNA and thereby affecting multiple cellular pathways simultaneously has the potential to improve docetaxel therapy of advanced prostate cancer.
|
29545934 |
2018 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, chrysin reduced expression of proliferating cell nuclear antigen in the prostate cancer cell lines compared to untreated prostate cancer cells.
|
28213961 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HnRNP-L promoted cell proliferation and tumor growth in Pca in part by interacting with endogenous p53 mRNA, which was closely associated with cyclin p21.
|
28038443 |
2017 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
GHRH increased both cell proliferation and proliferating cell nuclear antigen (PCNA) levels in LNCaP cells and in PC3 cells; however, such a rise was faster in the PC3 cells that represent the most aggressive stage of prostate cancer.
|
28193499 |
2017 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Antitumor effects of a novel small molecule targeting PCNA chromatin association in prostate cancer.
|
25253786 |
2014 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
|
21925791 |
2011 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report that TRPV6 is directly involved in the control of prostate cancer cell (LNCaP cell line) proliferation by decreasing: (i) proliferation rate; (ii) cell accumulation in the S-phase of cell cycle and (iii) proliferating cell nuclear antigen (PCNA) expression.
|
17533368 |
2007 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Semiquantitative reverse transcription-PCR analysis showed elevated E2F1 mRNA levels and increased levels of the E2F-target genes dihyrofolate reductase and proliferating cell nuclear antigen in metastatic hormone-independent prostate cancer cases compared with benign tissues.
|
17178887 |
2006 |
Prostate carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1b variant influences prostate cancer growth through aberrant androgen receptor regulation.
|
16461912 |
2006 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Detection of trisomy 7 with fluorescence in situ hybridization and its correlation with DNA content and proliferating cell nuclear antigen-positivity in prostate cancer.
|
9626793 |
1998 |
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Androgens regulate the expression of proliferating cell nuclear antigen posttranscriptionally in the human prostate cancer cell line, LNCaP.
|
8603399 |
1996 |
Prostate carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Proliferative activity determined by DNA flow cytometry and proliferating cell nuclear antigen (PCNA) immunohistochemistry as a prognostic factor in prostatic carcinoma.
|
1360498 |
1992 |